Articles On Opthea (ASX:OPT)

Opthea look to transform standard of care treatment for wet AMD to improve vision outcomes Two Phase 3 trials are underway investigating lead drug OPT-302 with results from both forecast mid 2025 Opthea looking to be first drug statistical...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Clarity says initial data from Phase 1/2 trial is positive Opthea completes enrolment of all patients in the COAST Phase 3 trial ProMedicus locks in record half   Clarity’s Phase 1/2 trial shows positive initial results Clarity Pharmaceut...

Opthea (ASX:OPT) has announced that it has completed the enrolment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept in combination with aflibercept.

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Opthea (ASX:OPT) has announced that CEO Dr Megan Baldwin will transition to founder and chief innovation officer, appointing US-based executives Dr Frederic Guerard as CEO and Peter Lang as chief financial officer.

Benchmark ASX index closes short by -0.04% Materials sector tries but cannot offset everyone else  Small caps led by HAL, DTC   The ASX200 Index has closed slightly lower after jumping early (+0.3%) out the gates on Wednesday morning. The...

Broker Rating Changes (PostThursday Last Week) Upgrade AMA GROUP LIMITED ((AMA)) Upgrade to Buy from Speculative Buy by Canaccord Genuity.B/H/S: 0/0/0 Having recently completed a $55m capital raise,AMA Group is set to deploy $35mto repay se...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead’s Top 10 at 11, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX 200 benchmark rises almost 0.6% Tech Sector recovers Wednesday’s losses, after Nasdaq positivity  Miners lead small cap gains, ERW, RDN, AZS winning at home in Andover South   The Australian share market was up and about early on Thur...

Melbourne-headquartered biotech company Opthea (ASX: OPT) has kicked off an $80 million capital raise to support clinical development of its drug candidate aimed at treating wet AMD (age-related macular degeneration), the most common cause...

The private equity giant has signalled its intention to take up an option to invest another $80 million in the clinical-stage biotech

Clinical-stage biopharmaceutical company Opthea (ASX:OPT) has announced that it is seeking to raise $80 million through a $10 million private placement and a $70 million entitlement offer.

Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year   Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Rumble Resources’s share price could double on zinc demand Opthea could rise more than 4x after Phase 3 completions Development Global has a portfolio of future facing metals   Wilsons says Rumble could double on zinc demand Wilsons Asset...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Highlights Imugene has advanced its ongoing Phase 1 MAST study with the first patients receiving dosing in the intratumoral (IT) and intravenous (IV) cohorts of CF33-hNIS in combination with Pembrolizumab. The study is focused on measu...

ASX 200 to rise on Tuesday ahead of the US CPI report Talk of extraterrestrial in US skies Manchester United reportedly for sale   The ASX 200 is poised to rise on Tuesday, tracking the rally in New York. At 8am AEDT, the ASX 200 Feb futu...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Jeremy Curnock Cook is the Managing Director and founder of BioScience Managers, a funds management business specialising in biotechnology investments in Australia and globally. He is also a director of Avita Medical Inc (ASX: AVH). Jeremy...

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

Lightning Minerals identifies multiple pegmatite intrusion outcrops at Dundas project Galan moves to 100pc ownership of the Green Bushes South Lithium Project Critical Resources’ recent assay results at Mavis Lake extends the current strik...

A decline in the stock market doesn’t mean you necessarily have to lose money Retail investors are not allowed to open a short-selling broker account in Australia But there is a handful of long-short and short-only funds available on the A...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

The Bendigo and Adelaide Bank Ltd (ASX: BEN) share price has suffered in August. It’s down by 16% in just two weeks. For a business as large as Bendigo Bank, that’s a significant fall in a short amount of time when the S&P/ASX 200...

The Beach Energy Ltd (ASX: BPT) share price plummeted 11% on Monday following the release of the company’s financial year 2022 earnings. The stock closed yesterday’s session at $1.645. Unfortunately, brokers shared in the market’s di...

Biopharmaceutical company Opthea (OPT) receives binding commitments for a US$90 million (A$127 million) two-tranche placement to institutional investors at $1.15 per share The clinical-stage healthcare stock has also secured up to US$170 m...

The Opthea Limited (ASX: OPT) share price closed 9.35% lower on Monday after the company announced details of a new share issue. Shares of the biopharmaceutical company finished the day at $1.26 each after opening at $1.39 this morning. Th...

The S&P/ASX 200 Index (ASX: XJO) is off to the races so far this Monday in a flying start to the week. At the time of writing, the ASX 200 has added a healthy 0.52% to back above 7,060 points. So let’s delve deeper into these gains an...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.6% to 7,072.6 points. Four ASX shares that have failed to follow the market higher today ar...

What, exactly, is a CEO’s job? It seems like a simple question. Maybe you even have a simple answer for it. Yes, the buck stops at the big desk in the corner office. That’s true. So ‘everything’ might be a good answer. Or, if youâ€...

The Bluescope Steel Ltd (ASX: BSL) share price is higher on Monday after the company impressed investors with its FY22 results. Shares in the steel producer currently trade hands for $17.74 each, a 5.03% gain, after reaching a high of $18....

The jury’s still out on the outlook for the big four ASX banks, but there’s one alternative ASX share that might be looking too cheap to ignore, according to a leading broker. The bank share in question is the Judo Capital Holdings Ltd...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. The stock market has...

Recent cap raising suggests biotechs may finally be making a comeback Mesblast annnounced a US$45m cap raise last week Today, Paradigm, Opthea, and Proteomics also announced fund raises Over the past year, the biotech sector has been caug...

The S&P/ASX 200 Materials Index (ASX: XMJ) is lifting 1.65% today, but three ASX mining shares are outperforming the index. The Belararox Ltd (ASX: BRX), Aurelia Metals Ltd (ASX: AMI) and Sarytogan Graphite Ltd (ASX: SGA) are all risi...

Opthea (ASX:OPT) has announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics to progress the development of OPT-302 for wet age-related macular degeneration....